With the threat of pharmaceutical tariffs hanging over the biopharmaceutical industry, Roche is the latest addition to a growing list of major drugmakers that are bolstering their manufacturing foo | The Swiss pharma's sweeping $50 billion investment comes as the threat of U.

Roche is pledging to invest $50 billion in manufacturing and research infrastructure in the U.S. over the next five years, making the pharmaceutical giant the latest company to unveil a capital expenditure push as drugmakers prepare for expected tariffs from the Trump administration.

Swiss drugmaker Roche (RHHBY) announced its decision to invest $50 billion in the U.S. towards pharmaceuticals and diagnostics over the next